BACKGROUND Asthma is characterized by a chronic airway inflammation, usually sustained by type 2 immunity. Bronchial and peripheral eosinophilia are biomarkers for type 2 asthma. Biologicals are the most effective treatment for severe asthma at present. Mepolizumab is an antagonist of interleukin-5 (IL-5), the most relevant cytokine involved in eosinophilia. OBJECTIVE This case report evaluated the effectiveness of mepolizumab in two girls with severe eosinophilic non-allergic asthma. MATERIALS AND METHODS Two female children with severe eosinophilic nonallergic asthma were treated with mepolizumab for two years. Clinical findings, lung function, peripheral eosinophils, asthma control, and bronchial endoscopy were performed. RESULTS Biologicals reduced the eosinophilia, asthma exacerbations, and improved lung function in both patients. The treatment was also safe and well-tolerated. CONCLUSION Mepolizumab represents an effective therapeutic option in the management of severe pediatric asthma.

中文翻译：

---

美泊利单抗对重度嗜酸性非过敏性哮喘儿童的类固醇节约作用。

背景哮喘以慢性气道炎症为特征，通常由2型免疫维持。支气管和外周嗜酸性粒细胞增多是 2 型哮喘的生物标志物。生物制剂是目前重症哮喘最有效的治疗方法。Mepolizumab 是白细胞介素 5 (IL-5) 的拮抗剂，白细胞介素 5 是与嗜酸性粒细胞增多最相关的细胞因子。目的 本病例报告评估了美泊利单抗对两名患有严重嗜酸性粒细胞性非过敏性哮喘的女孩的疗效。材料和方法 两名患有严重嗜酸性粒细胞性非过敏性哮喘的女童接受美泊利单抗治疗两年。进行了临床发现、肺功能、外周嗜酸性粒细胞、哮喘控制和支气管内窥镜检查。结果 Biologicals 减少了两名患者的嗜酸性粒细胞增多、哮喘发作并改善了肺功能。该治疗也是安全且耐受性良好的。结论美泊利单抗代表了治疗重症儿童哮喘的有效治疗选择。